Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months | Zendy

Nir Uriel | Zendy; P.C. Colombo | Zendy; Joseph C. Cleveland | Zendy; James W. Long | Zendy; Christopher T. Salerno | Zendy; Daniel J. Goldstein | Zendy; Chetan B. Patel | Zendy; Gregory A. Ewald | Zendy; Antone Tatooles | Zendy; Scott Silvestry | Zendy; Ranjit John | Zendy; Christiano Caldeira | Zendy; Valluvan Jeevanandam | Zendy; Andrew Boyle | Zendy; Kartik S. Sundareswaran | Zendy; Poornima Sood | Zendy; Mandeep R. Mehra | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months

Author(s) -

Nir Uriel,

P.C. Colombo,

Joseph C. Cleveland,

James W. Long,

Christopher T. Salerno,

Daniel J. Goldstein,

Chetan B. Patel,

Gregory A. Ewald,

Antone Tatooles,

Scott Silvestry,

Ranjit John,

Christiano Caldeira,

Valluvan Jeevanandam,

Andrew Boyle,

Kartik S. Sundareswaran,

Poornima Sood,

Mandeep R. Mehra

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.117.028303

Subject(s) - medicine , destination therapy , cohort , adverse effect , clinical endpoint , thrombosis , clinical trial , surgery , refractory (planetary science) , randomized controlled trial , stroke (engine) , cardiology , transplantation , heart transplantation , mechanical engineering , physics , astrobiology , engineering

The HeartMate 3 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated, continuous-flow blood pump engineered to enhance hemocompatibility and reduce shear stress on blood components. The MOMENTUM 3 trial (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares the HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical management, irrespective of therapeutic intention (bridge to transplant versus destination therapy). This investigation reported its primary outcome in the short-term cohort (n=294; 6-month follow-up), demonstrating superiority of the HM3 for the trial primary end point (survival free of a disabling stroke or reoperation to replace the pump for malfunction), driven by a reduced need for reoperations. The aim of this analysis was to evaluate the aggregate of hemocompatibility-related clinical adverse events (HRAEs) between the 2 LVAS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research